98%
921
2 minutes
20
Objective: Early personalized identification of SSc patients at risk of scleroderma renal crisis (SRC) can help provide better treatment and improve outcomes. This study aimed to create and validate a new multi-predictor Nomogram to predict SRC risk and compare it to an existing model.
Methods: A retrospective multicentre observational study was conducted using clinical data from SSc patients with SRC registered in the Chinese Rheumatism Data Center (CRDC) database. Each SSc patient with SRC was matched with four SSc patients without SRC, registered consecutively afterward, as controls. Differences between the two groups were analysed using Student's t-test, Mann-Whitney U test, χ2 test, or Fisher's exact test. Key risk factors were identified using univariate and multivariate logistic regression, as well as LASSO regression. The Nomogram's performance was assessed with receiver operating characteristic curves, calibration plots, decision curve analysis (DCA), and bootstrap resampling for internal and external validation. Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were used to compare models.
Results: The Nomogram incorporated predictive factors such as myocardial involvement, SSc subtype, anaemia, platelet count, and disease duration. The area under the ROC curve showed strong discrimination in both the training and validation datasets. Calibration curves and the Hosmer-Lemeshow test indicated good agreement between predicted and actual outcomes. DCA demonstrated greater clinical net benefit. The NRI and IDI results showed significant improvement over the previous model.
Conclusion: A Nomogram with improved predictive performance compared with the previous one was developed in a larger sample size in China.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/rheumatology/keaf034 | DOI Listing |
Mod Rheumatol
September 2025
Chugai Pharmaceutical Co., Ltd., 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo 103-8324, Japan.
ObjectivesThe 2023 EULAR guidelines for systemic sclerosis (SSc) newly recommend biologics (rituximab, tocilizumab), mycophenolate mofetil (MMF), and nintedanib in addition to cyclophosphamide for interstitial lung disease (ILD). This study investigated recent actual use of these drugs in Japan. MethodsWe analysed data from a Japanese hospital claims database (2020-2023), identifying patients with SSc disease codes (ICD-10 M34.
View Article and Find Full Text PDFArthritis Rheumatol
August 2025
Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Objective: To evaluate dynamic changes in autoantibody and proteomic profiles in treatment-naïve systemic sclerosis (SSc) patients and identify biomarkers and mechanisms associated with disease progression.
Methods: Serum samples from 30 baseline and 49 follow-up SSc patients, along with 38 controls, were analyzed. Autoantibody profiles were assessed using an autoantigen microarray targeting 120 autoantibodies, while proteomic analysis was conducted via liquid chromatography-mass spectrometry in data-independent acquisition mode.
Rheumatology (Oxford)
September 2025
Department of Rheumatology & Clinical Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Objectives: Many patients with systemic sclerosis (SSc) experience impaired hand function, yet the precise nature and impact of this impairment remains unclear. In this study, we explored the determinants of hand function impairment in SSc from a patient perspective and its impact on daily life. Additionally, we identified unmet care needs related to hand function impairment.
View Article and Find Full Text PDFKnee Surg Sports Traumatol Arthrosc
September 2025
Department of Orthopaedic Surgery, Yeosu Baek Hospital, Jeollanam-do, Republic of Korea.
Purpose: This study aimed to compare clinical outcomes between open and arthroscopic anterior latissimus dorsi (LD) transfer techniques for treating irreparable subscapularis (SSC) tears.
Methods: We retrospectively reviewed patients who underwent open or arthroscopic anterior LD transfer for irreparable SSC tears between February 2014 and August 2020. Patients were included if they had irreparable SSC tears with Lafosse Grade 4 or higher and Goutallier Grade 3 or higher, but without advanced arthritis (Hamada Grade < 3).
Nat Rev Rheumatol
September 2025
Division of Medicine, Royal Free Campus, University College London, London, UK.
Systemic sclerosis (SSc) is an autoimmune disease in which fibrotic, vascular, autoimmune and fibrotic mechanisms synergize to promote disease progression. SSc is associated with high morbidity and mortality, primarily owing to fibrotic tissue remodelling and subsequent organ failure. Despite progress with the approval of novel therapies, mortality remains high; approximately half of the people diagnosed with SSc will succumb to disease.
View Article and Find Full Text PDF